Environmental

Clinical-stage, low direct emissions: As a clinical-stage biopharma, Entrada Therapeutics has a limited environmental footprint compared to commercial manufacturers, with minimal direct emissions and resource use at this stage.

R&D focus, not manufacturing: The company’s operations are concentrated in research and development, with no evidence of large-scale manufacturing or supply chain impacts, reducing exposure to material environmental risks typical of the sector.

No published sustainability targets: There is no evidence of formal environmental sustainability policies, targets, or disclosures, which is common for early-stage biotech but lags best-in-class peers who proactively address future environmental impacts.

Entrada’s environmental risk profile is moderate, reflecting its limited operational footprint and early-stage focus. However, the absence of formal sustainability commitments or disclosures places it behind sector leaders as it approaches later-stage development.

Social

Talent attraction and retention: Recent inducement equity grants and competitive compensation packages highlight efforts to attract and retain specialized talent, a critical driver for clinical-stage biotech success.

Pipeline addresses high unmet needs: Entrada’s programs target severe neuromuscular and ocular diseases, including Duchenne muscular dystrophy, which supports a positive social impact if successful.

Limited workforce and diversity disclosure: There is no evidence of comprehensive workforce diversity, equity, or inclusion reporting, nor community engagement initiatives, which are increasingly expected by investors and stakeholders.

Entrada demonstrates moderate social performance, with strengths in talent management and a focus on high-impact diseases. However, limited transparency on workforce and community practices constrains its score relative to leading peers.

Governance

Experienced leadership and board oversight: The company is led by an experienced CEO and maintains an active board, with recent Compensation Committee actions reflecting standard governance practices for equity grants.

Strong capital discipline and cash runway: Entrada maintains a robust cash position ($327 million, funding into 3Q27) and low leverage (debt/equity 0.15x), supporting prudent financial oversight.

Shareholder alignment and transparency: Regular investor engagement, including participation in major healthcare conferences and timely disclosures, supports transparency, though the company lacks advanced governance features such as ESG-linked incentives or detailed risk oversight disclosures.

Governance practices are solid for a clinical-stage biotech, with strong financial controls and standard board oversight. The absence of advanced ESG governance features or detailed risk frameworks limits the score to moderate.

Overall Score

Entrada Therapeutics’ ESG profile is moderate across all pillars. The company’s early-stage focus limits its environmental and social risks but also results in less developed ESG policies and disclosures. Governance is sound but not differentiated. As the pipeline advances, ESG maturity and transparency will become increasingly important for peer competitiveness.